Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 253, Issue 8, 2015, Pages 1211-1216

  Jang, Liuna ^a,b,c   Gianniou, Christina ^a,b,c   Ambresin, Aude ^a,b,c   Mantel, Irmela ^a,b,c,d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b JULES GONIN EYE HOSPITAL   (Switzerland)

^c Jules Gonin Eye Hospital Fondation Asile des Aveugles (Foundation Asylum for the Blind)   (Switzerland)

^d HÔPITAL OPHTALMIQUE JULES GONIN   (Switzerland)

Author keywords

Anti VEGF; Intravitreal injections; Neovascular age related macular degeneration; Ranibizumab; Refractory subretinal fluid

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; INJECTION; MALE; MEDICAL RECORD REVIEW; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBRETINAL FLUID; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; RETREATMENT; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; RANIBIZUMAB; RETREATMENT; RETROSPECTIVE STUDIES; SUBRETINAL FLUID; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84938418571     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-014-2789-x     Document Type: Article

References (25)

1. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmol 114:246–252
2. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850–857
3. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:43–58
4. Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmol 119:1388–1398
5. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC, IVAN study investigators (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382:1258–1267
6. Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Pf L (2013) Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmol 120:1046–1056
7. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A, EXCITE Study Group (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmol 118:831–839
8. Abraham P, Yue H, Wilson L (2010) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 150:315–324
9. Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G, SUSTAIN Study Group (2011) Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmol 118:663–671
10. Dadgostar H, Ventura AACM, Chung JY, Sharma S, Kaiser PK (2009) Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmol 116:1740–1747
11. Rosenfeld Philip J, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B, MARINA and ANCHOR Study Groups (2011) Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmol 118:523–530
12. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. CATT research group. N Engl J Med 364:1897–908
13. Gupta OP, Shienbaum G, Patel AH, Fecarotta C, Kaiser RS, Regillo CD (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmol 117:2134–40
14. Mantel I, Zografos L, Ambresin A (2008) Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration. Ophthalmol 222:321–3
15. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünta C, Schmidt-Erfurth U, Tano Y, Wolf S (2010) Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 94:2–13
16. Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG (2013) Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study—a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 91:540–6
17. Tschuor P, Pilly B, Venugopal D, Gale RP (2013) Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark. Graefes Arch Clin Exp Ophthalmol 251:2327–30
18. Gerding H (2010) Treatment of wet AMD with less than 12 injections of ranibizumab per year. Klin Monbl Augenheilkd 227:284–7
19. Ersoy L, Ristau T, Kirchhof B, Liakopoulos S (2013) Response to anti-VEGF therapy in patients with subretinal fluid and pigment epithelial detachment on spectral-domain optical Cohen tomography. Graefes Arch Clin Exp OphthalmolThis is Graefes Arch Clin Exp Ophthalmol (2014) Jun 252(6):889–97
20. Konstantinidis L, Mantel I, Zografos L, Ambresin A (2010) Intravitreal ranibizumab in the treatment of choroidal neovascularization associated with idiopathic central serous chorioretinopathy. Eur J Ophthalmol 20:955–8
21. Roisman L, Ribeiro JC, Fechine FV, Lavinsky D, Moraes N, Campos M, Farah ME (2014) Does microperimetry have a prognostic value in central serous chorioretinopathy? Retina. 34(4):713–8
22. Fassnacht-Riederle H, Becker M, Graf N, Michel S (2014) Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp Ophthalmol Graefes Arch Clin Exp Ophthalmol. doi:10.1007/s00417-014-2589-3
23. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, Vavvas DG, Miller JW, Kim IK (2013) Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 156:29–35
24. Cho H, Shah CP, Weber M, Heier JS (2013) Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 97:1032–5
25. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB (2013) Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156:15–22